Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis

Previous studies show that long noncoding RNA intersectin 1-2 (lnc-ITSN1-2) promotes the inflammation process and serves as a potential biomarker in autoimmune diseases, except for ankylosing spondylitis (AS). Therefore, this study aimed to explore the correlation of baseline lnc-ITSN1-2 expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mingwu, Zhou, Xianjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514367/
https://www.ncbi.nlm.nih.gov/pubmed/34406596
http://dx.doi.org/10.1007/s10787-021-00854-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514367/
https://www.ncbi.nlm.nih.gov/pubmed/34406596
http://dx.doi.org/10.1007/s10787-021-00854-3

Ejemplares similares